Compare TG Therapeutics Inc (TGTX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Vanguard Total International Stock Index Fund ETF trades at $87.68. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | VXUS | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | Sector/Thematic |
52-Week High | $59.06 | $87.54 |
52-Week Low | $26.94 | $70.87 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
VXUS, the Vanguard Total International Stock ETF, trades at $87.54, up 0.82% today. The technical outlook is bullish based on moving averages, though oscillators are neutral and RSI levels suggest potential overbought conditions. Recent news highlights strong institutional buying and a 27.82% total return over the past year, emphasizing its role in diversifying beyond U.S. equities at a valuation discount.
The outlook for VXUS is positive, driven by international diversification benefits and strong recent performance. Key risks include global economic sensitivity and potential inflation impacts. Analyst sentiment is generally favorable, with institutional accumulation supporting long-term growth potential for investors seeking broad non-U.S. market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
